Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CRISPR-Cas9 lipid nanoparticle targeting APOE4
- Development stage
- Preclinical
- Lead developer
- Columbia University
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
CRISPR-Cas9 lipid nanoparticle targeting APOE4 is an experimental gene-editing therapeutic designed to treat Alzheimer's disease by reducing the expression of the apolipoprotein E ε4 (APOE4) allele, the strongest genetic risk factor for the condition. Developed by researchers at Columbia University, this nonviral platform utilizes lipid nanoparticles (LNPs) to deliver CRISPR-Cas9 components specifically to the brain. To overcome the blood-brain barrier, the treatment is administered systemically in conjunction with focused ultrasound (FUS)-mediated blood-brain barrier opening. Preclinical studies in transgenic mice have demonstrated that this approach can achieve significant APOE4 knockdown, leading to reduced amyloid-beta accumulation and attenuated neuroinflammatory responses, such as decreased astrocyte and microglial activation.
- Other names
- CRISPR-Cas9 LNPs targeting APOE4CRISPR-Cas-9 LNPs targeting APOE4CRISPR-Cas 9 LNPs targeting APOE4nonviral CRISPR therapeutics targeting APOE4
02
Targets
APOE4 (Apolipoprotein E4)
Beyond the preview
Go deeper on CRISPR-Cas9 lipid nanoparticle targeting APOE4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CRISPR-Cas9 lipid nanoparticle targeting APOE4.